Zer, A., Ratajczak, C., Adamu, H., Patel, S., Liu, Z., Xia, S., Zhang, N. (2025). TeliMET NSCLC-04: A phase 2, open-label, randomized, global study of 2 telisotuzumab vedotin regimens in patients with previously treated c-Met protein–overexpressing, locally advanced/metastatic non-squamous
            <i>EGFR</i>
            wildtype non-small cell lung cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8658